Eyenovia's Mydcombi Gets FDA Nod for Pupil Dilation

The US Food and Drug Administration (FDA) has approved Mydcombi (Eyenovia) for the dilation of pupils during diagnostic procedures.

The ophthalmic spray, made of 1% tropicamide and 2.5% phenylephrine hydrochloride, is the first agent approved for use with Eyenovia's Optejet dispenser, which distributes a fine mist that coats the surface of the eye.

"The use of eye dropper bottles has presented challenges for dosing in ophthalmologic settings in millions of patients," Sean Ianchulev, MD, founder of Eyenovia and chairman of its board of directors, said in a press release about the FDA approval. "We can do better now using sophisticated micro-array print delivery with physiologic dosing that is similar to the natural tear film volume."

The company said the product can be used for mydriasis prior to cataract surgery and for comprehensive eye exams.

Eyenovia said it will begin internal manufacturing for a 2024 rollout.

Clinicians should use caution in applying the drug in patients with cardiovascular disease and hyperthyroidism because of significant elevations in blood pressure, the company said. Common adverse reactions in clinical trials included transient blurred vision, reduced visual acuity, photophobia, and increased intraocular pressure. Some cases of rebound miosis were reported 1 day post administration.

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.

Credits:

Lead image: Kapil Joshi/Dreamstime

Image 1: Eyenovia

Cite this: Eyenovia's Mydcombi Gets FDA Nod for Pupil Dilation - Medscape - May 08, 2023.

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

My Alerts